20:19 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Bionomics discontinues BNC210 for PTSD after Phase II miss

Bionomics Ltd. (ASX:BNO; OTCQX;BNOEF) discontinued development of BNC210 to treat posttraumatic stress disorder (PTSD) after the compound missed the primary endpoint in the Phase II RESTORE trial in the indication. Twice-daily oral BNC210 did not...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

BNC210: Phase II data

Top-line data from the double-blind, placebo- and lorazepam-controlled, 4-way crossover, U.K. Phase II BNC210.006 trial in 24 patients with untreated GAD showed that a single oral dose of 300 mg BNC210 met the co-primary endpoints...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

BNC210: Completed Phase II enrollment

Bionomics completed enrollment of 24 patients in a double-blind, 4-way crossover, U.K. Phase II trial comparing 300 and 2,000 mg oral BNC210 vs. placebo or lorazepam. Bionomics Ltd. (ASX:BNO; OTCQX:BNOEF), Thebarton, Australia   Product: BNC210...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

BNC210: Phase Ib data

A double-blind, placebo-controlled, French Phase Ib trial in 54 healthy volunteers showed that once-daily doses of 300-2,000 mg oral BNC210 for 8 days were well tolerated. The maximum tolerated dose (MTD) was not reached and...
07:00 , May 25, 2015 |  BC Week In Review  |  Clinical News

BNC210: Phase II started

Bionomics began a double-blind, 4-way crossover, U.K. Phase II trial to compare 300 and 2,000 mg oral BNC210 vs. placebo or lorazepam in 24 patients. Bionomics Ltd. (ASX:BNO; OTCQX:BMICY), Thebarton, Australia   Product: BNC210  ...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

IW-2143: Phase Ib started

Bionomics began a double-blind, placebo-controlled, French Phase Ib trial to evaluate 4 dose levels of twice-daily oral BNC210 for 8 days in >50 healthy male volunteers. Bionomics Ltd. (ASX:BNO; OTCBB:BMICY), Thebarton, Australia   Product: IW-2143...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Bionomics, Ironwood deal

Bionomics and Ironwood mutually terminated a 2012 deal granting Ironwood exclusive, worldwide rights to develop and commercialize BNC210 . Bionomics, which regains rights to the anxiolytic compound, plans to further develop it before finding a...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

BNC210: Phase I started

Last month, Ironwood began a U.S. Phase I trial of single and multiple doses of IW-2143 in healthy volunteers. Bionomics granted Ironwood exclusive, worldwide rights to develop and commercialize IW-2143 in January 2012 (see BioCentury,...
08:00 , Jan 9, 2012 |  BC Week In Review  |  Company News

Bionomics, Ironwood deal

Bionomics granted Ironwood exclusive, worldwide rights to develop and commercialize BNC210 and other related compounds. Ironwood will be responsible for funding all clinical development of the products. Bionomics will receive $3 million up front and...
02:21 , Jan 6, 2012 |  BC Extra  |  Company News

Ironwood licenses Bionomics anxiety compound

Bionomics Ltd. (ASX:BNO; OTCBB:BMICY) granted Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) exclusive, worldwide rights to develop and commercialize BNC210 and related compounds. Bionomics will receive $3 million up front and is eligible for $342 million in milestones...